What counseling points should be given to a patient using ZORYVE (roflumilast) topical cream or foam?

Counseling Points for ZORYVE (Roflumilast) Cream

Patients using ZORYVE cream should be counseled that this is a once-daily topical medication for skin use only, with specific application instructions and awareness of common side effects including gastrointestinal symptoms and application site reactions.

Administration Instructions

Application technique:

• Apply ZORYVE cream once daily to affected areas only 11
• Rub the cream in completely until no longer visible on the skin 1
• Wash hands immediately after application 11
• If someone else applies the medication, they must also wash hands after application 1

Critical restrictions:

• Not for use in or on eyes, mouth, or vagina 111
• For external skin use only 1

Formulation-Specific Dosing

The specific strength depends on the indication and patient age:

For plaque psoriasis (ages ≥6 years):

• Use 0.3% cream strength 1

For atopic dermatitis:

• Adults and children ≥6 years: Use 0.15% cream strength 1
• Children 2-5 years: Use 0.05% cream strength 1

Expected Side Effects

Most common adverse reactions (≥1% incidence):

For plaque psoriasis patients 1:

• Diarrhea
• Headache
• Insomnia
• Nausea
• Application site pain
• Upper respiratory tract infections
• Urinary tract infections

For atopic dermatitis patients 2222:

• Headache
• Nausea
• Diarrhea
• Vomiting
• Application site pain (reported in 1.5% vs 0.7% with vehicle) 22
• Upper respiratory tract infections
• Rhinitis
• Conjunctivitis

Important tolerability note: Application site pain and stinging/burning causing definite discomfort occur in only 0.4-2.1% of patients, indicating excellent local tolerability 3.

Special Populations

Pregnancy:

• Unknown if ZORYVE cream will harm an unborn baby 1
• Discuss with healthcare provider if pregnant or planning pregnancy 1

Breastfeeding mothers - Critical instructions:

• Use on the smallest area of skin for the shortest duration possible while breastfeeding 11
• Do not apply directly to nipple or areola to avoid direct infant exposure 11
• Avoid inadvertent contact of treated areas with infant skin 1
• Unknown if roflumilast passes into breast milk 1

Liver disease:

• Contraindicated in moderate to severe liver impairment (Child-Pugh B or C) 1
• Inform healthcare provider of any liver problems 1

Drug Interactions

Warn patients about potential interactions:

• CYP3A4 inhibitors or dual CYP3A4/CYP1A2 inhibitors may increase roflumilast exposure and adverse reactions 1
• Oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast exposure 1
• Inform healthcare provider of all medications, including over-the-counter drugs, vitamins, and herbal supplements 1

Storage

• Store at room temperature: 20°C to 25°C (68°F to 77°F) 1
• Excursions permitted between 15°C and 30°C (59°F and 86°F) 1

Expected Timeline for Improvement

For atopic dermatitis:

• Significant improvement can be seen as early as Week 1-2 22
• Primary efficacy assessment at Week 4 222
• Long-term data shows sustained efficacy up to 52-56 weeks 3

For plaque psoriasis:

• Durable improvement observed through 52 weeks of treatment 4
• No tachyphylaxis (loss of effectiveness) observed with long-term use 4

When to Contact Healthcare Provider

• If symptoms worsen or do not improve
• If severe application site reactions develop
• If gastrointestinal symptoms (diarrhea, nausea, vomiting) become bothersome
• Before using any new medications concurrently
• If planning pregnancy or breastfeeding

Proactive Maintenance Strategy (for Atopic Dermatitis)

For patients who achieve clear skin (vIGA-AD score of 0) after 4 weeks of daily use:

• May switch to twice-weekly application to normal-appearing flare-prone areas 3
• This proactive approach maintains improvement for a median of 281 days 3
• Represents an alternative to reactive treatment only during flares 3